Medicare Enrolled

Dr. Haifaa Abdulhaq, MD

Hematology · Fresno, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
785 MEDICAL CENTER DRIVE WEST, Fresno, CA 93611
5593871900
In practice since 2008 (17 years)
NPI: 1508024647 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Abdulhaq from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Abdulhaq? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Abdulhaq

Dr. Haifaa Abdulhaq is a hematology specialist in Fresno, CA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Abdulhaq performed 2,190 Medicare services across 895 unique beneficiaries.

Between the years covered by Open Payments, Dr. Abdulhaq received a total of $273,177 from 58 pharmaceutical and/or device companies across 583 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Abdulhaq is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice ▲ Top 16% volume in CA $273,177 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,190
Medicare services
Top 16% in CA for hematology
895
Unique beneficiaries
$89
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~129 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
1,317 $94 $318
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
215 $139 $439
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
131 $93 $293
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
122 $59 $219
Vitamin B-12 injection
An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg.
107 $1 $4
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
106 $10 $45
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
57 $120 $428
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
51 $59 $197
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
45 $97 $336
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
20 $138 $465
New patient office visit, complex (60-74 min) 19 $172 $559
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$273,177
Total received (2018-2024)
Avg $39,025/year across 7 years
Top 7% in CA for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
58
Companies
583
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$138,632 (50.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$109,588 (40.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$24,957 (9.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$72,048
2023
$50,972
2022
$35,971
2021
$23,865
2020
$17,283
2019
$43,701
2018
$29,336

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
F. Hoffmann-La Roche AG
$19,797
Genentech USA, Inc.
$16,994
ABBVIE INC.
$10,067
AstraZeneca Pharmaceuticals LP
$9,296
Novartis Pharmaceuticals Corporation
$5,513
Genmab U.S., Inc.
$4,180
E.R. Squibb & Sons, L.L.C.
$3,061
PFIZER INC.
$1,184
Celgene Corporation
$334
Alexion Pharmaceuticals, Inc.
$199
Genentech, Inc.
$149
Janssen Biotech, Inc.
$139
GlaxoSmithKline, LLC.
$134
Rigel Pharmaceuticals, Inc.
$121
Astellas Pharma US Inc
$102
GENZYME CORPORATION
$95
Boehringer Ingelheim Pharmaceuticals, Inc.
$81
SOBI, INC
$76
Eisai Inc.
$73
Exelixis Inc.
$64
SpringWorks Therapeutics, Inc.
$59
SERVIER PHARMACEUTICALS LLC
$50
Ipsen Biopharmaceuticals, Inc
$48
Takeda Pharmaceuticals U.S.A., Inc.
$37
Apellis Pharmaceuticals, Inc.
$28
TAIHO ONCOLOGY, INC.
$25
ARRAY BIOPHARMA INC
$23
Merck Sharp & Dohme LLC
$23
Incyte Corporation
$20
Blueprint Medicines Corporation
$19
PharmaEssentia USA Corporation
$17
EMD Serono, Inc.
$15
Daiichi Sankyo Inc.
$14
Agios Pharmaceuticals, Inc.
$13
Top 3 companies account for 65.0% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$51,702
Novartis Pharmaceuticals Corporation
$42,126
Astellas Pharma US Inc
$35,289
F. Hoffmann-La Roche AG
$19,797
Amgen Inc.
$14,617
Genentech, Inc.
$14,344
E.R. Squibb & Sons, L.L.C.
$14,334
Alexion Pharmaceuticals, Inc.
$12,404
ABBVIE INC.
$11,769
AstraZeneca Pharmaceuticals LP
$11,711
Acrotech Biopharma LLC
$6,515
MorphoSys AG
$5,391
Genmab U.S., Inc.
$4,180
Janssen Scientific Affairs, LLC
$4,039
Celgene Corporation
$3,208
PFIZER INC.
$3,130
MorphoSys, US Inc.
$3,095
AbbVie Inc.
$3,069
Kite Pharma, Inc.
$2,479
SERVIER PHARMACEUTICALS LLC
$2,119
Incyte Corporation
$1,573
Karyopharm Therapeutics Inc.
$1,563
Janssen Global Services, LLC
$1,500
Janssen Biotech, Inc.
$430
GENZYME CORPORATION
$286
Apellis Pharmaceuticals, Inc.
$244
GlaxoSmithKline, LLC.
$227
Takeda Pharmaceuticals U.S.A., Inc.
$202
Seagen Inc.
$195
Epizyme, Inc.
$165
Lilly USA, LLC
$149
Rigel Pharmaceuticals, Inc.
$121
Daiichi Sankyo Inc.
$102
ADC Therapeutics America, Inc.
$99
SOBI, INC
$95
Exelixis Inc.
$81
Boehringer Ingelheim Pharmaceuticals, Inc.
$81
Eisai Inc.
$73
Pharmacyclics LLC, An AbbVie Company
$72
Adaptive Biotechnologies Corporation
$64
Octapharma USA, Inc.
$63
Agios Pharmaceuticals, Inc.
$60
SpringWorks Therapeutics, Inc.
$59
Ipsen Biopharmaceuticals, Inc
$48
Gilead Sciences, Inc.
$40
Bayer Healthcare Pharmaceuticals Inc.
$28
TAIHO ONCOLOGY, INC.
$25
Spectrum Pharmaceuticals Inc.
$24
ARRAY BIOPHARMA INC
$23
Merck Sharp & Dohme LLC
$23
Sun Pharmaceutical Industries Inc.
$22
Pharmacosmos Therapeutics Inc.
$21
Blueprint Medicines Corporation
$19
PORTOLA PHARMACEUTICALS, LLC
$18
PharmaEssentia USA Corporation
$17
Regeneron Healthcare Solutions, Inc.
$15
Secura Bio, Inc.
$15
EMD Serono, Inc.
$15
Top 3 companies account for 47.3% of all-time payments
Associated products mentioned in payments ›
ALUNBRIG · ANDEXXA · AYVAKIT · Abraxane · BELEODAQ · BESPONSA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CHANTIX · CREON · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Empaveli · Enhertu · Erleada · FARYDAK · Fabhalta · Folotyn · GILOTRIF · IBRANCE · ICLUSIG · INJECTAFER · Imbruvica · JEMPERLI · KEYTRUDA · KISQALI · KYMRIAH · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · Nubeqa · ODOMZO · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · Onivyde · PADCEV · PLUVICTO · PROMACTA · PYRUKYND · Polivy · Pomalyst · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · SARCLISA · SCEMBLIX · SOLIRIS · SPRYCEL · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · Tazverik · Tecartus · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · Vanflyta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XOSPATA · XPOVIO · XTANDI · Xospata · Xtandi · ZEJULA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (51%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for hematology in CA.

Looking for a hematology specialist in Fresno?
Compare hematologists in the Fresno area by procedure volume, costs, and industry payment transparency.
Browse hematologists nearby

Geographic Context

Hematologists within 10 mi
2
Per 100K population
0.2
County median income
$71,434
Nearest hospital
CLOVIS COMMUNITY MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Abdulhaq is a clinical cardiology specialist, with above-average Medicare volume (top 16% in CA), with speaking/promotional industry engagement in the top 7% of CA peers, with 17 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Abdulhaq experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Abdulhaq performed 1,317 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Abdulhaq receive payments from pharmaceutical companies?
Yes. Dr. Abdulhaq received a total of $273,177 from 58 companies across 583 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Abdulhaq's costs compare to other hematologists in Fresno?
Dr. Abdulhaq's average Medicare payment per service is $89. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Abdulhaq) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →